Verhoeckx Kitty, Lindholm Bøgh Katrine, Constable Anne, Epstein Michelle M, Hoffmann Sommergruber Karin, Holzhauser Thomas, Houben Geert, Kuehn Annette, Roggen Erwin, O'Mahony Liam, Remington Ben, Crevel René
1TNO, Utrechtseweg 48, Zeist, The Netherlands.
2National Food Institute, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark.
Clin Transl Allergy. 2020 May 18;10:13. doi: 10.1186/s13601-020-00318-x. eCollection 2020.
The growing world population and increased pressure on agricultural resources are driving a shortage of dietary protein sources. As a result, industry is developing more sustainable novel food protein sources such as insects, algae and duckweed and using new processing techniques. Consumer exposure to these novel or processed proteins, could cause new food allergies, exacerbating a public health issue which is already directly affecting an estimated 20 million Europeans. Introduction of novel foods should not add to the burden of food allergy and this calls for a reliable, harmonised, evidence-based and validated allergenicity risk assessment strategy. The COST (Cooperation in Science and Technology) Action ImpARAS (Improved Allergenicity Risk Assessment Strategy), a four-year networking project, identified gaps in current allergy risk assessment, and proposed new ideas and plans for improving it. Here, we report on the lessons learned from the ImpARAS network and suggestions for future research. The safe introduction of novel and more sustainable food protein sources, while protecting humans from food allergy, calls for a multidisciplinary approach based on an improved understanding of what determines the relative allergenic potency of proteins, novel testing and assessment methodologies, harmonized decision-making criteria, and a clear ranking approach to express the allergenicity of novel product relative to that of existing known allergenic proteins: (from 'non'/to weakly and to strongly allergenic proteins).
世界人口的增长以及农业资源压力的增加,正导致膳食蛋白质来源短缺。因此,食品行业正在开发更具可持续性的新型食品蛋白质来源,如昆虫、藻类和浮萍,并采用新的加工技术。消费者接触这些新型或加工过的蛋白质,可能会引发新的食物过敏,使一个已经直接影响到约2000万欧洲人的公共卫生问题更加严重。新型食品的引入不应增加食物过敏的负担,这就需要一个可靠、统一、基于证据且经过验证的致敏性风险评估策略。“科技合作”(COST)行动“改进致敏性风险评估策略”(ImpARAS)是一个为期四年的网络项目,该项目找出了当前过敏风险评估中的差距,并提出了改进的新思路和计划。在此,我们报告从ImpARAS网络中学到的经验教训以及对未来研究的建议。在保护人类免受食物过敏的同时,安全引入新型且更具可持续性的食品蛋白质来源,需要采取多学科方法,这基于对决定蛋白质相对致敏效力因素的更好理解、新的测试和评估方法、统一的决策标准,以及一种明确的分级方法,以表达新型产品相对于现有已知致敏蛋白质的致敏性(从“无”致敏性到弱致敏性再到强致敏性蛋白质)。